| Date | Title | Description |
| 11.03.2026 | World Sleep Day 2026 Unites 70+ Countries to Advance Sleep Health | Communities in more than 70 countries will unite on March 13 for World Sleep Day 2026, a global call to action led by World Sleep Society to elevate healthy sleep as essential to health and well-being at every stage of life.
World Sleep Day... |
| 10.11.2025 | [CIIE] Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply | (Yicai) Nov. 10 -- Simcere Pharmaceutical Group showed its redefined cross-border collaboration model at the eighth China International Import Expo, with the Chinese company to soon start manufacturing in China an insomnia drug it licensed ... |
| 31.10.2025 | Financial success for publicly traded biotech companies |
Idorsia is a Basel-based biotech company focused on the discovery, development, and commercialization of transformative medicines – either with in-house capabilities or together with partners. Its lead candidate QUVIVIQ™ (daridorexant) is ... |
| 14.10.2025 | Financial boost for publicly traded scale-ups |
ADC Therapeutics SA, a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in ... |
| 24.09.2025 | Business and clinical advancements propel Swiss biotech companies |
Topadur is currently conducting a Phase 2a clinical trial evaluating TOP-N53 in patients with systemic sclerosis-related digital ulcers, a rare, life-threatening autoimmune disease characterized by fibrosis, vascular damage, and chronic di... |
| 22.08.2025 | UK’s FTSE 100 posts best week since May; Europe markets close higher as Fed rate cut hopes mount | European stock markets closed higher on Friday, as investors continued to assess the full scope of the European Union’s trade deal with America and hopes rose for a U.S. interest rate cut in September.
The pan-European Stoxx 600 provisional... |
| 11.06.2025 | The New Wave of Leadership and Innovation in Swiss Startups | In the heart of Switzerland, a revolution is brewing. Startups are not just sprouting; they are evolving. With fresh leadership and innovative products, these companies are poised to reshape their industries. The recent appointments of new ... |
| 10.06.2025 | Neue Power für Startup-Geschäftsleitungen |
Payrexx, ein hierzulande führender Zahlungsdienstleister für KMU, ernennt Hendrik Schulenburg zum neuen Chief Financial Officer (CFO). Der 24-jährige Ökonom kam 2021 während seinem Bachelor in Business Administration an der Frankfurt Schoo... |
| 27.03.2025 | Idorsia publishes its Annual Report 2024 | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – March 27, 2025
Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, Governance Report, Compensation Report... |
| 17.03.2025 | US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients | Ad hoc announcement pursuant to Art. 53 LR
FDA confirms that prescribers and pharmacists are no longer expected to interact with the REMS
Allschwil, Switzerland – March 17, 2025
Idorsia Ltd (SIX: IDIA) today announced that – effective immed... |
| 06.03.2025 | Idorsia restructures its financial position and raises CHF 150 million |
Based in Allschwil, Idorsia is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs, primarily in neuroscience, cardiovascular, and immunology, has recently reached a major miles... |
| 27.02.2025 | Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call | Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET.
An investor webcast and conference call will be held to discuss the results on the same day.
Date: Tuesday, March 4, 2025
Time: 14:00 CET / ... |
| 12.02.2025 | Idorsia publishes the resolutions for the upcoming bondholder meeting | Ad hoc announcement pursuant to Art. 53 LR
The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted upon
Unaudited Financial Status as of December 31, 2024 – requ... |
| 31.01.2025 | Owkin Doses First Patient in Phase I Trial of AI-Optimized Cancer Therapy OKN4395 | What You Should Know:
– Owkin, an AI-powered biotech company, today announced the dosing of the first patient in its Phase I clinical trial of OKN4395, a novel cancer therapy designed to restore immune function in patients with advanced sol... |
| 15.01.2025 | Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders | Ad hoc announcement pursuant to Art. 53 LR
Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand
Allschwil, Switzerland – January 15, 2025
Idorsia Ltd (SIX: IDIA) today announced... |
| 14.01.2025 | Idorsia publishes an invitation to a bondholder meeting | Ad hoc announcement pursuant to Art. 53 LR
A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on January 17, 2025, including an extension of the m... |
| 20.12.2024 | Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan | Ad hoc announcement pursuant to Art. 53 LR
Company announces delay to the targeted timeline for signing a binding agreement
Company in discussions with bondholders to restructure the company’s outstanding debt and extend the operational cas... |
| 11.11.2024 | Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions | Allschwil, Switzerland – November 11, 2024
Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, will be presented at ... |
| 29.10.2024 | Idorsia announces financial results for the first nine months of 2024 | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 29, 2024
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024.
Highlights
Net revenue 9M 2024 at CHF 53 million.
US GAAP ... |
| 17.09.2024 | Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 | Allschwil, Switzerland – September 17, 2024
Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with chronic insomnia, will be presented a... |
| 05.09.2024 | New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 | Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award
Allschwil, Switzerland – September 5, 2024
Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagon... |
| 02.09.2024 | Amended terms of Idorsia’s 2024 convertible bonds become effective | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – September 2, 2024
Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the amended terms of Idorsia’s... |
| 25.07.2024 | Idorsia announces financial results for the first half 2024 | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – July 25, 2024
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024.
Business highlights
Viatris collaboration: Global research and devel... |
| 01.07.2024 | Three biotech companies report progress on the way to the market |
The European Commission (EC) has approved Idorsia’s JERAYGO (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. Hypertension is one of the lea... |
| 25.06.2024 | Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – June 25, 2024
Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere kantonale Nachlassbehörde) (the Court) in relatio... |
| 13.06.2024 | Idorsia holds its Annual General Meeting of Shareholders | All Board proposals approved by the shareholders
Allschwil, Switzerland – June 13, 2024
At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board... |
| 09.05.2024 | Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges | PITTSBURGH, May 9, 2024 /PRNewswire/ --
Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Opera... |
| 23.04.2024 | New report presents good figures from the Swiss biotech sector as high flyers flourish |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is quite positive. In addition to record revenues of CHF 7.3 billion, the industry raised more than CHF 2 billion – a remarkable 50% increase ove... |
| 20.03.2024 | FDA approvals and encouraging results for innovative therapies |
Idorsia announced today that the US Food and Drug Administration (FDA) has approved TRYVIO (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are... |
| 05.03.2024 | Business wind down and take off for listed Swiss startups |
Since its inception in 2012, ObsEva SA (SIX: OBSN) has focused on the development of novel therapies for women's health and pregnancy, with a program focused on improving in vitro fertilization success rates. Due to low cash reserves, the ... |
| 28.02.2024 | Idorsia and Viatris enter into a significant global research and development collaboration | Ad hoc announcement pursuant to Art. 53 LR
Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.
Idorsia to receive an upfront payment of USD 350 million, poten... |
| 20.07.2023 | Idorsia sells its Asia Pacific operations to Sosei Heptares for CHF 400 million | |
| 20.06.2023 | Fresh money for Santhera and Idorsia | |
| 06.04.2023 | Idorsia issues invitation to the 2023 Annual General Meeting of Shareholders | Allschwil, Switzerland – April 6, 2023
Idorsia Ltd IDIA today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year endin... |
| 31.01.2023 | Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension | The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated
Allschwil, Switzerland – Ja... |
| 20.12.2022 | Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension | The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated
Allschwil, Switzerland – De... |
| 20.12.2022 | Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension | The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated
/EIN News/ -- Allschwil, Sw... |
| 12.12.2022 | Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs | Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuation Exploratory efficac... |
| 12.12.2022 | Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs | Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuation
Exploratory efficac... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for daridorexant in China | NANJING, China, Nov. 16, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the disc... |
| 16.11.2022 | Simcere and Idorsia enter into a licensing agreement for daridorexant in China | NANJING, China, Nov. 15, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd IDIA "Idorsia"), specialized in the discovery, ... |
| 15.11.2022 | Idorsia’s insomnia drug available in first European countries | |
| 13.11.2022 | Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award | Martine Clozel was selected for the Prix Suisse award for her contribution to research, science, and medicine and was presented with the Prix Suisse by the National Council President Irène Kälin The Prix Suisse is an annual award presented ... |
| 25.10.2022 | Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 25, 2022
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2022.
Commercial highlights
QUVIVIQ™ (daridorexant) acceleration... |
| 20.10.2022 | Invitation to Idorsia's nine-month financial results 2022 webcast and conference call | Idorsia will publish its financial results for the first nine months of 2022 on October 25, 2022, at 07:00 CEST.
An investor conference call and webcast will be held to discuss the results on the same day.
Date: Tuesday, October 25, 2022
Ti... |
| 03.10.2022 | Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia | Ad hoc announcement pursuant to Art. 53 LR
Daridorexant demonstrated significant improvement in the subjective measures of Total Sleep Time (sTST) and Latency for Sleep Onset (sLSO) in Japanese patients with insomnia
Idorsia Japan expects t... |
| 12.09.2022 | Six New Member Companies Join the International Consortium for Innovation and Quality in Pharmaceutical Development | IQ continues to grow as an organization and advance key industry initiatives while delivering innovative approaches and effective therapies to patients. We look forward to mutually beneficial collaboration and progress of our portfolio to e... |
| 26.07.2022 | Idorsia announces financial results for the first half 2022 – reaching commercial stage | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – July 26, 2022
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2022.
Commercial highlights
QUVIVIQ™ (daridorexant) was launched in the US... |
| 19.07.2022 | Invitation to Idorsia's half year financial results 2022 webcast and conference call | Idorsia will publish its half year financial results 2022 on Tuesday July 26, 2022, at 07:00 CEST.
An investor conference call and webcast will be held to discuss the results on the same day.
Date: Tuesday, July 26, 2022
Time: 14:00 CEST / ... |
| 23.05.2022 | Idorsia claims PhIII win for hypertension drug at center of $230M J&J deal | Months after earning its first approval, Idorsia is back with a Phase III win for a different, J&J-partnered drug.
The Swiss biotech said aprocitentan, its dual endothelin receptor antagonist, has aced a late-stage tria... |
| 03.05.2022 | Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder | QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning
Comprehensive nighttime efficacy and unique daytime function... |
| 02.05.2022 | Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia | In the US, QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance1
QUVIVIQ becomes Idorsia’s first commerc... |
| 26.04.2022 | Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – April 26, 2022
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2022.
Business highlights
PIVLAZ™ (clazosentan) for the prevention of ... |
| 14.04.2022 | Idorsia holds its Annual General Meeting of Shareholders | Ad hoc announcement pursuant to Art. 53 LR
All Board proposals approved by the Shareholders
Allschwil, Switzerland – April 14, 2022
At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Allschwil, Switzerland, sharehold... |
| 07.04.2022 | Eldico Scientific opens world’s first experience centre for electron diffraction | |
| 04.04.2022 | The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage | Results published in the Journal of Neurosurgery show that clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings.
The pivotal studies in ... |
| 10.03.2022 | New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022 | Allschwil, Switzerland – March 10, 2022
Idorsia Ltd (SIX: IDIA) today announced that new data for daridorexant in patients with insomnia disorder, including long-term safety and efficacy data, will be presented at World Sleep 2022, a global... |
| 03.03.2022 | Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – March 3, 2022
Idorsia Ltd (SIX: IDIA) today issued the formal Notice to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The m... |
| 08.02.2022 | Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025 | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – February 8, 2022
Idorsia Ltd (SIX: IDIA) today announced its financial results for 2021.
Business highlights
QUVIVIQ™ (daridorexant) 25 mg and 50 mg approved by the US Food... |
| 08.02.2022 | Idorsia : Download (2.5MB) | Governance Report
20
21ANNUAL REPORT
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
We have more ideas, we see more opportunities and we want to transform the horizon of therapeu... |
| 08.02.2022 | Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025 | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – February 8, 2022
Idorsia Ltd (SIX: IDIA) today announced its financial results for 2021.
Business highlights
QUVIVIQ™ (daridorexant) 25 mg and 50 mg approved by the US Food... |
| 01.02.2022 | Invitation to Idorsia's full year financial results 2021 webcast and conference call | Idorsia will publish its full year financial results 2021 on Tuesday February 8, 2022, at 07:00 CET.
An investor conference call and webcast will be held to discuss the results on the same day.
Date: Tuesday, February 8, 2022
Time: 14:00 CE... |
| 26.01.2022 | Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada | Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada
Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant ... |
| 24.01.2022 | Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development | Ad hoc announcement pursuant to Art. 53 LR
Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development
Guy Braunstein, currently Head of Global Clinical Development, to assume newly cre... |
| 20.01.2022 | Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg | Ad hoc announcement pursuant to Art. 53 LR
Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg
Allschwil, Switzerland – January 20, 2022
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals Japan today announce that... |
| 20.01.2022 | Idorsia : The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia | Media Release
January 20, 2022
The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
As reported in the Lancet Neurology, daridorexant is the first insomnia medication... |
| 20.01.2022 | The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia | The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
As reported in the Lancet Neurology, daridorexant is the first insomnia medication to demonstrate an effect of a ... |
| 12.01.2022 | Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep | Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep
Jennifer reveals for the first time her sleep story spanning many years of challenges... |
| 10.01.2022 | FDA approves Idorsia’s insomnia drug | |
| 10.01.2022 | Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia | Ad hoc announcement pursuant to Art. 53 LR
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
The approval of QUVIVIQ™ – 25 & 50 mg – is based on a robust Phase 3 clinical p... |
| 10.01.2022 | Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA | Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA
QUVIVIQ™ (daridorexant) – 25 and 50 mg – approved by the US FDA for the treatment of adults wi... |
| 13.12.2021 | Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study | Ad hoc announcement pursuant to Art. 53 LR
Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study
Idorsia will consult with health authorities and sha... |
| 01.11.2021 | Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus | Ad hoc announcement pursuant to Art. 53 LR
Cenerimod 4 mg showed clinically meaningful improvement in the mSLEDAI-2K* primary efficacy endpoint and other measures of efficacy, consistent with the effect seen on biological activity
Effect of... |
| 27.10.2021 | Johnson & Johnson partially converts its convertible loan | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 27, 2021
Idorsia Ltd (SIX: IDIA) today announced that Cilag Holding AG, an indirect subsidiary of Johnson & Johnson, notified Idorsia that it will convert a sec... |
| 26.10.2021 | Idorsia : Financial Report Nine-Month 2021 | Financial
Report
20
21NINE-MONTH
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic ... |
| 26.10.2021 | Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 26, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial results for the third quarter of 2021.
Business highlights
Five Idorsia affiliates in key European ma... |
| 26.10.2021 | Press Release : Idorsia announces financial -2- | On July 28, 2021, Idorsia placed CHF 600 million senior unsecured convertible bonds (the "Bonds"), due 2028. The Bonds have a maturity of 7 years and are convertible into 19.0 million newly issued registered shares of Idorsia, sou... |
| 26.10.2021 | Idorsia : announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 26, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial results for the third quarter of 2021.
Business highlights
Five Idorsia affiliates in key European ma... |
| 26.10.2021 | Press Release : Idorsia announces financial -3- | ACT-777991 - Immunology Phase 1 ------------- ---------------- ---------------------------------------- -----------------------------------
* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole co... |
| 11.10.2021 | Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – October 11, 2021
Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as an oral substrate reduction therapy for ... |
| 11.10.2021 | Idorsia : announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease | Media Release
October 11, 2021
Ad hoc announcement pursuant to Art. 53 LR
Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease
Allschwil, Switzerland - October 11, 2021
Idorsia Ltd (SIX: IDIA) today announ... |
| 28.07.2021 | Idorsia : successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company | Media Release
July 28, 2021
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS.
This ... |
| 28.07.2021 | Press Release : Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company | Ad hoc announcement pursuant to Art. 53 LR
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICA... |
| 28.07.2021 | Idorsia : launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company | Media Release
July 28, 2021
Ad hoc announcement pursuant to Art. 53 LR
NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WO... |
| 27.07.2021 | Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company | Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – July 27, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021.
Business highlights
Daridorexant for the treatment of insomnia under... |
| 27.07.2021 | Idorsia : Media Release (English) | Media Release
July 27, 2021
Ad hoc announcement pursuant to Art. 53 LR
Idorsia announces financial results for the first half 2021 - Building momentum towards becoming a fully-fledged biopharmaceutical company
Allschwil, Switzerland - July ... |
| 27.07.2021 | Press Release : Idorsia announces financial -2- | At the end of the first half of 2021, Idorsia's liquidity (including cash, cash equivalents, short- and long-term deposits) amounted to CHF 927 million.
(in CHF millions) Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 -------------------------- ---... |
| 28.06.2021 | Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction | Ad hoc announcement pursuant to Art. 53 LR
Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST
Allschwil, Switzerland – June 28, 2021
Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 ... |
| 22.04.2021 | IDORSIA LTD
Press Release : Idorsia announces financial -2- | --------------------------- ------------ ------------ ------------ Long-term deposits 196 192 180 --------------------------- ------------ ------------ ------------ Total liquidity* 1,065 1,200 632 --------------------------- ------------ -... |
| 01.04.2021 | IDORSIA LTD
Idorsia : issues Notice of the 2021 Annual General Meeting of Shareholders | Allschwil, Switzerland – April 1, 2021
Idorsia Ltd (SIX: IDIA) today issued the formal Notice to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of th... |
| 01.04.2021 | IDORSIA LTD
Press Release: Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders | Allschwil, Switzerland -- April 1, 2021 Idorsia Ltd (SIX: IDIA) today issued the formal Notice to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of t... |
| 10.03.2021 | FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia | • The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable... |
| 01.03.2021 | Idorsia submits NDA for clazosentan to Japanese PMDA | Allschwil, Switzerland – March 1, 2021
Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endoth... |
| 04.02.2021 | Idorsia : announces financial results for 2020 – a successful year marked by outstanding clinical data | Allschwil, Switzerland – February 4, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020.
Business highlights
Positive results in the Phase 3 program of daridorexant, demonstrating improved overall slee... |
| 04.02.2021 | Press Release : Idorsia announces financial -2- | binge-like eating behavior in animal models. Our study will be the first to study orexin 1 receptor antagonism as a new mechanism of action for patients with eating disorders. The company is also initiating a Phase 1 clinical pharmacology p... |
| 04.02.2021 | IDORSIA LTD
Press Release : Idorsia announces financial -2- | binge-like eating behavior in animal models. Our study will be the first to study orexin 1 receptor antagonism as a new mechanism of action for patients with eating disorders. The company is also initiating a Phase 1 clinical pharmacology p... |
| 04.02.2021 | IDORSIA LTD
Idorsia : announces financial results for 2020 – a successful year marked by outstanding clinical data | Allschwil, Switzerland – February 4, 2021
Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020.
Business highlights
Positive results in the Phase 3 program of daridorexant, demonstrating improved overall slee... |
| 22.10.2020 | Idorsia completes capital increase of CHF 535.5 million | Idorsia Ltd announced that a total of 23,800,000 new shares were sold in connection with the at-market rights offering, of which 15,825,319 new shares were subscribed to by existing shareholders in the rights offering and 7,974,681 new shar... |
| 22.10.2020 | Idorsia completes capital increase of CHF 535.5 million | |
| 21.10.2020 | IDORSIA LTD
Idorsia : raises $600 million to support insomnia drug launch | Idorsia plans to file for approval for daridorexant in the United States later this year and is already building up a sales team, in hopes of getting a swift nod from the U.S. Food and Drug Administration.
Company founders Jean-Paul and Mar... |
